Identification of at-risk populations varies by scale used, which could impact clinical practice
The FDA has accepted for review the New Drug Application for vibegron (Urovant Sciences) for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
New study results reinforce OAB guidelines recommending behavioral therapy as first-line treatment.
Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The NDA submission includes data from an extensive clinical development program involving over 4000 patients with…
Similar proportions of black and white men had each type of nocturia.
In a prospective study, the odds of dementia increased nearly 50% with daily use of anticholinergics for 3 years at the minimum effective dose recommended for older adults.
An over-the-counter device to treat stress urinary incontinence (SUI) in women has been made available by Rinovum Women’s Health.
Updated OAB guideline now says clinicians may consider combination therapy with an antimuscarinic and beta3-andrenoceptor agonist for patients refractory to monotherapy with either of those medications.
Velicept Therapeutics announced that solabegron met the primary endpoint in the phase 2b VEL-2002 study that evaluated patients with overactive bladder (OAB).
Urovant Sciences announced topline data from the phase 3 EMPOWUR trial which evaluated vibegron in adult patients with symptoms of overactive bladder.